NASDAQ:TENX Tenax Therapeutics Q2 2026 Earnings Report $1.84 +0.02 (+0.82%) As of 01:36 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tenax Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.38Beat/MissN/AOne Year Ago EPSN/ATenax Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATenax Therapeutics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tenax Therapeutics Earnings HeadlinesPiper Sandler Remains a Buy on Tenax Therapeutics (TENX)September 16 at 9:24 AM | theglobeandmail.comAdar1 Capital Management, Llc Buys 900,000 Shares of Tenax Therapeutics (NASDAQ:TENX) StockSeptember 10, 2026 | americanbankingnews.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 17 at 1:00 AM | Decentralized Masters (Ad)Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 9, 2026 | americanbankingnews.comTenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?September 4, 2026 | insidermonkey.comGuggenheim downgrades Tenax Therapeutics (TENX)September 2, 2026 | msn.comSee More Tenax Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email. Email Address About Tenax TherapeuticsTenax Therapeutics (NASDAQ:TENX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for pulmonary hypertension and cardiovascular diseases. The company’s primary development program is centered on levosimendan, a calcium sensitizer and potassium-channel opener being evaluated for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Tenax is developing an oral formulation of levosimendan under the name TNX-103, along with other potential formulations intended for use in cardiovascular and pulmonary vascular conditions. The company’s research and development activities are aimed at addressing diseases for which treatment options remain limited, including pulmonary hypertension involving the right side of the heart. Tenax has historically operated as a development-stage biopharmaceutical company and has pursued rights to develop and commercialize levosimendan in North America. Its programs remain focused on clinical development and regulatory advancement rather than the sale of an established commercial product portfolio.View Tenax Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageHoliday Shopping Is Almost Here—And Target May Be Ready to Win BigCan ServisFirst Keep Delivering?Banc of California Bets on Short-Term Pain3 Luxury Consumer Brands to Watch in a Beaten-Down SectorJackson’s Record Quarter Powers the Bull Case Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
